NASDAQ:ELVN Enliven Therapeutics Q3 2026 Earnings Date & Estimates $41.52 -0.41 (-0.98%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$41.86 +0.34 (+0.83%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Enliven Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for November 9, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeAfter Market ClosesConference Call DateNovember 9, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Enliven Therapeutics in Q3 2026Enliven Therapeutics is expected to post earnings of -$0.4478 per share. In the same quarter a year earlier Enliven Therapeutics reported -$0.32 per share. Enliven Therapeutics last reported on August 5, 2026, posting -$0.49 per share and missing the -$0.3872 consensus estimate. Enliven Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.4478Prior-Year EPS-$0.32Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.49 (Missed by -$0.1028)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Enliven Therapeutics Q3 2026 Earnings FAQ When does Enliven Therapeutics report Q3 2026 earnings? Enliven Therapeutics (NASDAQ:ELVN) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Enliven Therapeutics' Q3 2026 earnings call? Enliven Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Enliven Therapeutics? Analysts expect Enliven Therapeutics to post earnings of -$0.4478 per share for Q3 2026. Enliven Therapeutics Earnings HeadlinesWhat is HC Wainwright's Estimate for ELVN Q3 Earnings?October 23 at 1:13 AM | americanbankingnews.comBrokers Set Expectations for ELVN FY2027 EarningsOctober 22 at 1:13 AM | americanbankingnews.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.October 25 at 1:00 AM | Decentralized Masters (Ad)HC Wainwright Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock PriceOctober 19, 2026 | americanbankingnews.comEnliven Therapeutics, Inc. Announces Appointment of Kristine Ball to Board of Directors, Effective October 14, 2026October 15, 2026 | marketscreener.comMEnliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearOctober 15, 2026 | finanznachrichten.deSee More Enliven Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email. Email Address About Enliven TherapeuticsEnliven Therapeutics (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes. Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors. Both programs are being evaluated in clinical development, and the company may expand its pipeline through additional internally discovered oncology programs. Enliven Therapeutics is based in Boulder, Colorado, and focuses primarily on the development of medicines for cancer patients in the United States and other potential international markets. The company was co-founded by Sam Kintz, who serves as its chief executive officer.View Enliven Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineNewmont’s Record Quarter Shows Why Gold’s Floor Is the Real StoryLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestCan Planet Fitness Get Its Growth Back in Shape?Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
